Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Bullboard (TSXV:ARCH)

View:
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
Post by Riverfolkon Oct 30, 2021 11:06am

House Positions Last Week

House Positions for C:ARCH from 20211025 to 20211029 House Bought $Val Ave Sold $Val Ave Net $Net ...more  
82
Post by stocksarefunon Oct 30, 2021 8:46am

Should we enter phase 3....

I have never owned a ticker that has moved from phase 2 to phase 3.  For those who have been down this road before, what are the likely next steps? - Is dilution and a big capital raise to fund ...more  
161
Post by stocksarefunon Oct 28, 2021 11:41am

Accumulation tricks nearly done

This daily U shaped price action is no longer working. Volume drying up again on these movements. None of the core shareholders are falling for the fake outs anymore. Feels like consolidation in this ...more  
143
Post by SrPlataon Oct 27, 2021 8:16pm

Steps on getting to $20 USD

First off I realize we are a long way to $20, Yes I know that first we have to get to $3,4,5 etc first and I am not looking for it overnight (unless they is a buyout) First step  Get Peer review ...more  
246
Post by Riverfolkon Oct 25, 2021 12:02pm

Human Clinical Trial Results Pending 3rd Party Review - DD

  Here is the science published by a world renounced third party: Dipeptidase-1 ( Metablok)  mice, with survival increasing from 0% to 83 ...more  
170
Post by Riverfolkon Oct 25, 2021 11:47am

Arch Biopartners Historic Bought Financings

  Dec 23, 2020 (One Placee) announced it has closed the non-brokered private placement the Company disclosed in a press release December 23, 2020 (The “Offering”). Pursuant to the ...more  
198
Post by Riverfolkon Oct 25, 2021 11:42am

Extremely Undervalued in Comparison to peers

The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peers. Current Market cap 130 mil US  ...more  
205
Comment by stocksarefunon Oct 24, 2021 11:50pm

RE:RE:RE:Terrific buying opportunity this morning

I'm not sure, no more details beyond what was shared. No idea who it is at RJ either. 
79
Discussion
Post by TheBearInTheWoodson Oct 22, 2021 9:02pm

Had a moment of weakness today

Was close to panic selling like everyone else today, then I remembered.... hey, the government paid for this trial and it doesn't look like Arch is raising money before news..... so, why would I ...more  
198
Comment by Antonius2on Oct 22, 2021 5:34pm

RE:RE:Terrific buying opportunity this morning

Hi Stocksarefun, Do you know whether David Novak, Managing Director of Equity Research Analyst of Healthcare & Biotechnology at Raymond James name was mentioned in your grapevine?
95
Discussion
Post by TheBearInTheWoodson Oct 22, 2021 4:37pm

Today’s house position

House Positions for C:ARCH from 20211022 to 20211022 House Bought $Val Ave Sold $Val Ave Net $Net ...more  
167
Comment by stocksarefunon Oct 22, 2021 12:08pm

RE:Terrific buying opportunity this morning

Intersting. From what I've heard through the grapevine, RJ has a buy analyst waiting for phase 3 results to initiate coverage on ARCH with a ~10$ buy target.  Sounds like a classic ...more  
137
Discussion
Comment by GoldenArmon Oct 22, 2021 11:01am

RE:Fear

Excellent analysis. 100% agreement
69
Discussion
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities